Business Wire

CA-TETRATE

Share
Envoy Gateway Makes Using Envoy Proxy Easier for Developers and Reverses Fragmentation

Members of the steering group for Envoy Gateway (EG), including Envoy creator Matt Klein and representatives from Ambassador Labs, Fidelity Investments, Tetrate, and VMware, Inc., today announced their joint commitment to the project, which launched today at KubeCon + CloudNativeCon, Europe 2022, under the auspices of the Cloud Native Computing Foundation® (CNCF®). Envoy Gateway is a new effort within the Envoy proxy open source project to simplify Envoy use in cloud-native application development.

Envoy Gateway will reduce existing, redundant efforts around Envoy and make it much easier for application developers to use Envoy as a basic API gateway “out of the box” and as a Kubernetes Ingress controller. Exposing a simplified set of APIs, and implementing the Kubernetes Gateway API, EG makes it easier to extend Envoy. Developers will now have a cost-free, unfettered way to provide external access to their work in progress. At the same time, Envoy Gateway will not replace API management features currently found in commercial products.

“Envoy has achieved a great deal of success since we first released it in 2016,” said Matt Klein, founder of the Envoy proxy project. “And community has been at the heart of Envoy from the beginning. With the community-driven Envoy Gateway project, we see the opportunity to make Envoy accessible to many more users through the addition of simplified APIs and new capabilities explicitly targeted at north-south / edge proxy use cases.”

Envoy is already widely used for traffic between separate services in a microservices application—that is, east-west traffic. With Envoy Gateway, Envoy will also be easy to use for north-south traffic—traffic between an application and the outside world, as with consumers of an application’s APIs.

Envoy Gateway—Extensible Open Source Infrastructure for the Cloud-Native Future

IT organizations worldwide want to establish and use a rich, robust, modern stack of open source software for cloud-native application development and delivery, under the management of organizations such as the Linux Foundation and CNCF. Commercial offerings and projects within each IT team can then add value on top of this core infrastructure.

Envoy is fast becoming the go-to networking substrate within this modern, cloud-native stack. However, the need for API access, traffic routing, and other ingress capabilities has recently led to fragmentation in the Envoy ecosystem. Envoy Gateway will bring this needed functionality back into the main Envoy project and make it less confusing and time-consuming for developers to access Envoy.

Implementation Via Kubernetes Gateway API

Envoy Gateway will expose a version of the Kubernetes-native Gateway API , with Envoy-specific extensions. This is an expressive, extensible, role-oriented API well-suited to use by developers. Gateway API is either implemented, or in progress, for Istio, the Contour project (which originated at VMware), Emissary-ingress (which originated at Ambassador Labs), and others.

When users create Gateway API resources, they will be translated into native Envoy API calls, so Envoy and xDS, its native API, will not need to be changed to add this new support.

Advantages for Developers, Infrastructure Administrators and Business Decision-Makers

Application developers will experience the most positive impact from Envoy Gateway. They will be able to run Envoy Gateway and begin routing traffic to their applications. They will no longer need to build their own control plane, or extend an existing control plane such as a Go or Java control plane, or bring in a vendor solution at the early stages of their projects. They can just configure routes for the application and share them.

Infrastructure administrators will be able to easily offer an Envoy-native experience to application teams, without needing to adopt a vendor solution just to get basic gateway functionality. They will be able to manage instances of Envoy Gateway without interfering with developer access to them. Envoy Gateway will allow them to deliver consistent application networking capabilities across heterogeneous environments.

Executives and decision-makers will have Envoy as a standard and, we expect, widely-used solution for API access and Kubernetes ingress. They will also benefit from faster and easier development and delivery of more secure and robust software and services.

Additional Resources

  • Explore CNCF announcements .
  • Review the official blog of the Envoy project.
  • Learn more about Envoy Gateway goals .

About Envoy

Originally created by Matt Klein and built at Lyft, Envoy is a high performance C++ distributed proxy designed for single services and applications, as well as a communication bus and “universal data plane” designed for large microservice “service mesh” architectures. Built on the learnings of solutions such as NGINX, HAProxy, hardware load balancers, and cloud load balancers, Envoy runs alongside every application and abstracts the network by providing common features in a platform-agnostic manner. When all service traffic in an infrastructure flows via an Envoy mesh, it becomes easy to visualize problem areas via consistent observability, tune overall performance, and add substrate features in a single place.

Contact Matt Klein at mattklein123@gmail.com .

About Ambassador Labs

Ambassador Labs, the cloud native developer experience leader, enables developers to code, test, ship, and run applications faster and easier than ever. Maker of top Cloud Native Computing Foundation (CNCF) open source projects, including Emissary-ingress and Telepresence, Ambassador Labs delivers a developer control plane for Kubernetes that integrates the development, deployment, and production infrastructure for developers and organizations worldwide including Microsoft, PTC, NVidia, and Ticketmaster. Ambassador Labs is backed by top investors including Insight Partners and Matrix Partners. Learn more and get started for free at www.getambassador.io .

Contact Lisa Williams of Ambassador Labs at lisawilliams@datawire.io .

About Fidelity Investments

Fidelity’s mission is to inspire better futures and deliver better outcomes for the customers and businesses we serve. With assets under administration of $11.3 trillion, including discretionary assets of $4.2 trillion as of March 31, 2022, we focus on meeting the unique needs of a diverse set of customers. Privately held for over 75 years, Fidelity employs more than 57,000 associates who are focused on the long-term success of our customers. For more information about Fidelity Investments, visit www.fidelity.com/about-fidelity/our-company .

Contact Kathleen Bentley of Fidelity Investments at kathleen.bentley@fmr.com .

About Tetrate

Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Customers get consistent, baked-in observability, runtime security and traffic management in any environment. Tetrate continues to serve as a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io .

Contact Annie Fink of Bospar at annie@bospar.com .

About VMware

VMware is a leading provider of multi-cloud services for all apps, enabling digital innovation with enterprise control. As a trusted foundation to accelerate innovation, VMware software gives businesses the flexibility and choice they need to build the future. Headquartered in Palo Alto, California, VMware is committed to building a better future through the company’s 2030 Agenda. For more information, please visit www.vmware.com/company .

Contact Eloy Ontiveros of VMware Global Communications at eontiveros@vmware.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye